Trial · NCT02066402
Adverse events60
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 60
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Tedizolid Phosphate (Sivextro, BAY119-2631) | 7 | 292 | |
| other | Diarrhoea | Gastrointestinal disorders | Linezolid | 8 | 297 | |
| other | Nausea | Gastrointestinal disorders | Tedizolid Phosphate (Sivextro, BAY119-2631) | 15 | 292 | |
| other | Nausea | Gastrointestinal disorders | Linezolid | 14 | 297 | |
| other | Fatigue | General disorders | Tedizolid Phosphate (Sivextro, BAY119-2631) | 3 | 292 | |
| other | Fatigue | General disorders | Linezolid | 6 | 297 | |
| other | Injection site extravasation | General disorders | Tedizolid Phosphate (Sivextro, BAY119-2631) | 5 | 292 | |
| other | Injection site extravasation | General disorders | Linezolid | 6 | 297 | |
| other | Pyrexia | General disorders | Tedizolid Phosphate (Sivextro, BAY119-2631) | 10 | 292 | |
| other | Pyrexia | General disorders | Linezolid | 5 | 297 | |
| other | Hepatic function abnormal | Hepatobiliary disorders | Tedizolid Phosphate (Sivextro, BAY119-2631) | 2 | 292 | |
| other | Hepatic function abnormal | Hepatobiliary disorders | Linezolid | 7 | 297 | |
| other | Cellulitis | Infections and infestations | Tedizolid Phosphate (Sivextro, BAY119-2631) | 7 | 292 | |
| other | Cellulitis | Infections and infestations | Linezolid | 9 | 297 | |
| other | Skin bacterial infection | Infections and infestations | Tedizolid Phosphate (Sivextro, BAY119-2631) | 6 | 292 | |
| other | Skin bacterial infection | Infections and infestations | Linezolid | 7 | 297 | |
| other | Alanine aminotransferase increased | Investigations | Tedizolid Phosphate (Sivextro, BAY119-2631) | 7 | 292 | |
| other | Alanine aminotransferase increased | Investigations | Linezolid | 6 | 297 | |
| other | Aspartate aminotransferase increased | Investigations | Tedizolid Phosphate (Sivextro, BAY119-2631) | 7 | 292 | |
| other | Aspartate aminotransferase increased | Investigations | Linezolid | 6 | 297 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02066402/events